The way to prevent sapa
(57) Abstract:The use of medicine to prevent disease low glanders in sensitive to P mallei mammals. The inventive protein with a molecular mass of 37 - 30 KD, vydelennaya from the outer cell wall spnego microbe and presumably perform the function of steam formation, injected subcutaneously sensitive to Sapa mammals at the rate of 10 to 30,000 mg per kg of body weight. After 12 - 27 d immunization repeat. The method ensures the survival of 83% Golden hamsters infected subcutaneously with 50 - 100 lethal doses agar culture of the highly virulent strain. table 2. The invention relates to medicine, in particular to methods of prevention of infectious diseases, and can be used to prevent infection low glanders in sensitive P. mallei mammals.Against Sapa not developed methods of specific prophylaxis. Working with this pathogen is carried out under the conditions required mechanical protection of the eye, hand and respiratory tract. Infected animals usually kill, burn corpses.Closest to the claimed is the method lies in the effects of antibacterial drugs (sulfanilyl).The method is used exclusively for personal prophylaxis of the individuals involved in the accident 
The disadvantage of this method is nespecificnomu steps used to prevent Sapa medicines. In the result, preventive measures are not purposeful in nature and can be implemented only after human contact with the causative agent of glanders, when it became known representatives of the medical service. Due to their non-specificity of the method cannot be used for large-scale prevention of glanders in animals.The aim of the invention is the creation of a mammal-specific resistance to infection with P. mallei.The goal is achieved due to the impact on sensitive agent of glanders mammalian proteins with a molecular mass 37-40 KD isolated from the cell wall of the pathogen Sapa.The invention is based on the first detected the ability of this protein, the causative agent of glanders to have a protective effect against sapnay infection.The essence of the proposed method is as follows.A protein with a molecular mass 37-40 KD, purified from cytoplasmic proteins and peptidoglycan the ssy. Through 12-27 day immunization repeat. To determine the protective effect perform subcutaneous or airborne contamination of animals virulent culture of P. mallei in quantities sufficient to cause their death. Within 30 days daily basis, record the number of dead animals. Protective effect is defined as the ratio of the LD 50 virulent strain for vaccinated animals to the LD 50 for intact (resistance index). While infecting a culture of a virulent strain of P. mallei index of resistance depends on the dose and frequency of drug administration. The method ensured the survival of 83% Golden hamsters infected subcutaneously 50-100 deadly infective doses agar culture a highly virulent strain of P. mallei C-5.The essential feature of the claimed invention is that a protein with a molecular mass 37-40 KD isolated from the outer membrane of the cell wall of the pathogen Sapa, has a strong immunoprotective effect, which is related to the fact that the main function of this protein in the cell wall is the formation of pores for low molecular weight substances. Between the essential feature of the claimed object and achievable technical result there is a causal relationship, the proteins, porins, forming on the surface of the bacterial wall channels for the passage of solutes, leading to disruption of normal metabolism of bacteria that conical end and is the cause of their death.Another possible mechanism for the prevention of infectious process can be stimulating specific cellular immunity by facilitating recognition by the immune system (cells, performing killer function) spnego microbe. Important in clarifying the mechanisms of development of a protective effect achieved in this way is the fact that some bacterial porins play the role of one of the pathogenic factors, facilitating their penetration into mammalian cells. The causative agent of glanders is an intracellular parasite, so any interaction of the antibody with its surface proteins and porins especially, leads to disruption of adhesion of this agent on the surfaces of target cells.Preparations of membrane protein with a molecular mass 37-40 KD does not have a toxic effect against Golden hamsters at doses of 30 mg/kg weight of the animal. The detection ability of this protein to induce specific immunity is. delanie purinovogo protein from a culture of a strain of P. mallei C-5.To highlight purinovogo protein was used the method developed Novikova O. D. for Yersinia pseudotuberculosis microbe (Novikova O. D. a pore-forming protein from the outer membrane of Yersinia pseudotuberculosis. Chemical characterization and biological activity: Dis.Kida.Biol.Sciences. Vladivostok, 1986). The method consists in the following. To 6 g of acetone-dried cells of the pathogen Sapa add 600 ml of chilled saline solution and within 2 hours the cells are suspended on a magnetic stirrer at a temperature of 42aboutC. and Then cooled by centrifugation for 45 min at 600 g. The residue is suspended in 200 ml of 0.03 M Tris-Hcl buffer (pH 7,2) (hereinafter buffer A), containing 2% Triton X 100, and extracted at a temperature of 42aboutC for 2 h under vigorous stirring. The precipitate was separated by centrifugation at 20000 g for 15 min, washed with buffer And suspended in 200 ml of buffer, add 2 ml of 1M solution of MgCl and 10 mg dnaase (Reachim NGO Biochemical) and incubated for 12 hThe precipitate was separated by centrifugation at 20000 g for 30 min, washed with buffer And suspended in 150 ml of buffer a containing 2% sodium dodecyl sulfate, and extracted at temperaturesThe precipitate is washed with water, suspended it in 100 ml of buffer A, containing 0.5% sodium dodecyl sulfate and 0.5 M NaCl, incubated at a temperature of 370,5aboutC for 30 minutes and Then the precipitate was separated by centrifugation at 100000 g for 30 minutes Suspended it in 50 ml of buffer a containing 2% sodium dodecyl sulfate, and heated in a water bath for 10 minutesThe precipitate was separated by centrifugation at 150000 g for 1 h Then cleaning are gelfiltration in sephacryl S-200 or other media. The selected drug is a hydrophobic protein with a molecular mass 37-40 kilodaltons. In reaction diffusion precipitation diagnostic sera to the agent of glanders forms a clear line.For membership in the selected protein to proteins of class Parinov says the following: the allocation Novikova O. D. can only be used to highlight a pore-forming protein, a protein localized in the outer membrane and is closely related to lipopolysaccharide; exhibits a pronounced hydrophobic properties and insoluble in water; it has the ability to induce a pronounced species-specific immunity; molecular mass of the monomer 37-40 KD that membrane proteins typical for Parinov.O p s t 1. To determine the specific protective effect of animals were vaccinated subcutaneously twice with an interval of 21 days. The dose for each injection of 25 mg of antigen (protein) animal (animal weight 100 g). After 18 days after the second vaccination, animals were infected subcutaneously two-day agar culture of the strain P. mallei 5584. As control was used Intertie animals. The results of the experiment are given in table.1.The definition of a protective effect derived the claimed invention in experimental Sapa Golden hamsters
O p s t 2. To study the possibility of increasing the protective action porina immunization was carried out with different doses and concentrations of drug.The conditions of the experiment and the results are shown in table. 2. Animal infections were performed as described in experiment No. 1. The WAY to PREVENT SAPA, including effects on the body medicamental means, characterized in that the impact of implementing isolated from the cell wall spnego microbe proteins mol. m 37 - 40 KD, which perform the role of species-specific antigen and induce the immunization in animals species-specific immunity to the pathogen sa is
FIELD: medicine, purulent surgery.
SUBSTANCE: one should perform generally accepted medicinal therapy, moreover, one should prescribe additional chemotrypsin during the first 1-2 d after operation to be locally injected twice-thrice during day-time period at concentration of 0.5-1.0 mg/ml of 10%-sodium chloride solution at exposure of 1.5-2 h at the quantity of one fourth up to one third against the purulent volume removed out of abscess cavity, then therapy course should be supplemented with bacteriophage which should be locally injected twice during day-time period at daily dosage being 200 ml, not more at exposure of 1.5-2 h at the quantity of one tenth up to one fifth against purulent volume removed out of abscess cavity. As for bacteriophage type, it should be matched in accordance to the results of bacteriological survey of abscess cavitary content. Therapy course lasts for 6-9 d.
EFFECT: higher efficiency of therapy.
FIELD: veterinary science.
SUBSTANCE: one should collect summer colostrums in cows to be filtered, poured into sterile tanks per 1-1.5 l and frozen in freezing chambers at -20 - -22 C. In winter-spring period colostrums should be gradually defrosted while calves are being calved. To remove casein in raw material one should apply abomasal enzyme - pepsin (4-6 g pepsin/l colostrum). This enzyme should be added into colostrums heated up to 38 C. After casein precipitation on should filter the whey to be conserved with potassium sorbate (1 g potassium sorbate/l whey). The method is very simple and enables to obtain high-quality preparation.
EFFECT: higher efficiency.
1 dwg, 1 ex, 1 tbl
FIELD: medicine, neurology.
SUBSTANCE: method involves intravenous administration of autolymphocytes treated with an immunomodulating agent by extracorporal method using cycloferon (250 mg) as an immunomodulating agent. Simultaneously, the following medicinal mixture comprising lidocaine, 100 mg; lidazum, 32 U; dexamethasone, 4 mg; leukinferon, 10 000 U; 40% glucose solution, 4 ml is administrated into interspinal ligaments of spinal column at levels corresponding to thoracal and lumbar enlargements of the spinal cord. The procedure is repeated three times with interval for 48-72 h. Method provides enhancing the effectiveness of lymphostimulation and immunomodulation in cerebrospinal sclerosis. Invention can be used for lymphostimulation and immunomodulation in cerebrospinal sclerosis.
EFFECT: improved method for treatment.
1 tbl, 1 ex
FIELD: medicine, gastroenterology.
SUBSTANCE: invention relates to methods for treatment of chronic helicobacter pylori-associated gastritis. Method is carried out by monotherapy with the probiotic "Laminolakt" in the dose 3 dragees per 24 h for 1 month. Method provides elimination of Helicobacter pylori cells on the background of activation of the immune response in stomach mucosa by effect on microflora and the colon intestine immune system.
EFFECT: enhanced effectiveness of treatment.
2 tbl, 1 ex
FIELD: pharmaceutical industry.
SUBSTANCE: pharmaceutical form contains (i) peptides with aggregation tendency in the form of their salts: acetates, gluconates, glucuronates, lactates, citrates, benzoates, or phosphates, which are dissolved of dispersed, and (ii) acids corresponding to above-listed salts.
EFFECT: lowered aggregation tendency and improved release of active substance resulting in improved bioavailability of peptide active substances.
22 cl, 9 tbl, 3 ex
FIELD: chemistry of peptides, medicine, cardiology, pharmacy.
SUBSTANCE: invention relates to medicinal agents used for treatment of cardiovascular system diseases. Invention proposes new tetrapeptide alanyl-glutamyl-aspartyl-arginine of the general formula: Ala-Glu-Asp-Arg of the sequence 1 [SEQ ID NO:1] eliciting biological activity and displaying in recovery of function of myocardium. Invention proposes pharmacological agent comprising the effective dose of tetrapeptide alanyl-glutamyl-aspartyl-arginine of the general formula: Ala-Glu-Asp-Arg as an active peptide agent of the sequence 1 [SEQ ID NO:1] that elicits biological activity and displaying in recovery of function of myocardium. Using new tetrapeptide Ala-Glu-Asp-Arg as component of medicinal agent promotes to recovery of function of myocardium. Invention can be used as an agent recovering function of myocardium in treatment of different form of this pathology.
EFFECT: valuable medicinal properties of peptide.
4 cl, 9 tbl, 1 dwg, 9 ex
FIELD: medicine, pulmonology, peptides, pharmacy.
SUBSTANCE: invention relates to medicinal agents used for treatment of diseases of respiratory system. Invention proposes new tetrapeptide alanyl-glutamyl-aspartyl-leucine of the general formula: Ala-Glu-Asp-Leu eliciting biological activity and displaying in recovery of functions of respiratory organs. Invention proposes pharmacological agent comprising the effective dose of tetrapeptide alanyl-glutamyl-aspartyl-leucine of the general formula: Ala-Glu-Asp-Leu as an active peptide agent. Using new tetrapeptide as component of medicinal agent promotes to recovery of functions of respiratory organs. Invention can be used as agent recovering function of respiratory organs in treatment of different forms of pulmonary pathology.
EFFECT: valuable medicinal properties of peptide.
4 cl, 8 tbl, 1 dwg, 6 ex
FIELD: medicine, endocrinology.
SUBSTANCE: invention relates to treatment of diabetes mellitus in mammals. Invention proposes applying inhibitors of enzyme dipeptidyl peptidase IV as an active component in manufacturing a medicinal agent, and in a method for treatment of diabetes mellitus. Invention provides enhancing the functional activity of insulin-producing cells in animal and differentiation of epithelial cells of the pancreas.
EFFECT: improved method for insulin producing and diabetes treatment.
20 cl, 5 dwg, 2 tbl, 2 ex
FIELD: medicine, oncology.
SUBSTANCE: invention elates to treatment of tumors. Method involves administration of aplidine in the dose not exceeding the recommended dose and limiting by the toxicity of the preparation in patient and in the correspondence of one the following schedule: 24 h infusion, once time per a week for 3 weeks and with the following one resting week; 24 h infusion, once time per two weeks; 1 h infusion, once per a week for 3 weeks in each 4 weeks; 1 h infusion, once per a day for 5 days for 3 weeks; 3 h infusion by each the second week. Applying indicated regimens enhances the effectiveness of treatment of malignant tumors being among them with resistance to the conventional treatment and in combination with the absence of the therapy toxicity.
EFFECT: improved and enhanced effectiveness of treatment.
4 cl, 15 dwg, 18 ex
FIELD: pharmaceutical, food and cosmetic industry.
SUBSTANCE: invention relates to a method for preparing peptide-enriched biologically active serum. Method for preparing biologically active serum involves carrying out acid and alkaline hydrolysis of plant amaranth under definite conditions and mechanical treatment of the preparation obtained as result of two-stage hydrolysis and this preparation is converted to form useful for storage. Invention elates to a method for preparing biologically active serum involving successive acidic and alkaline hydrolysis of plant amaranth under definite conditions with addition of on alga taken among the following group: focus, sacchariferous laminaria, laminaria japonica and mechanical treatment of the preparation obtained after two-stage hydrolysis that is converted to form useful for storage. Serum comprises the enhanced amount of peptide, improved organoleptic indices and activated antioxidant system.
EFFECT: improved preparing method, enhanced properties of serum.
14 cl, 6 ex